The effect of silymarin on liver injury induced by Thioacetamide in rats
Najmeh Kabiri, Ahangar-Darabi Mahboobeh, Mahbubeh Setorki, Rafieian-kopaei Mahmoud
Abstract
Najmeh Kabiri, Ahangar-Darabi Mahboobeh, Mahbubeh Setorki, Rafieian-kopaei Mahmoud
Abstract
Introduction: In this study the protective effects of Silymarin was investigated against thioacetamide (TAA) induced hepatotoxicity in rat. Methods: In an experimental study 24 male Wistar rats were designated in four equal groups as follows: Control group, the group treated with thioacetamide (TAA), Silymarin (400 mg/kg for 3 weeks) + TAA (400 mg/kg), TAA (400 mg/kg) + Silymarin (400 mg/kg for 3 weeks). The levels of serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) lactate dehydrogenase (LDH) and total bilirubin were measured to assess the hepatotoxicity and hepatoprotection. Results: TAA significantly increased AST, ALT, ALP, LDH and bilirubin. Treatment by Silymarin caused a significant reduction in serum levels of AST, ALT, ALP, LDH and bilirubin contents. Conclusion: The results indicate a protective effect for Silymarin against thioacetamide induced hepatotoxicity which might be due to its ability to block the bioactivity of thioacetamide.
OpenAlex reports 16 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Introduction: In this study the protective effects of Silymarin was investigated against thioacetamide (TAA) induced hepatotoxicity in rat. Methods: In an experimental study 24 male Wistar rats were designated in four equal groups as follows: Control group, the group treated with thioacetamide (TAA), Silymarin (400 mg/kg for 3 weeks) + TAA (400 mg/kg), TAA (400 mg/kg) + Silymarin (400 mg/kg for 3 weeks). The levels of serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) lactate dehydrogenase (LDH) and total bilirubin were measured to assess the hepatotoxicity and hepatoprotection. Results: TAA significantly increased AST, ALT, ALP, LDH and bilirubin. Treatment by Silymarin caused a significant reduction in serum levels of AST, ALT, ALP, LDH and bilirubin contents. Conclusion: The results indicate a protective effect for Silymarin against thioacetamide induced hepatotoxicity which might be due to its ability to block the bioactivity of thioacetamide.
Key concepts: Thioacetamide, Alkaline phosphatase, Lactate dehydrogenase, Hepatoprotection, Bilirubin, Chemistry, Alanine transaminase, Pharmacology